Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy : A Case Series
Copyright © 2018 by the American Society of Nephrology..
BACKGROUND AND OBJECTIVES: C3 glomerulopathy is a form of complement-mediated GN. Immunosuppressive therapy may be beneficial in the treatment of C3 glomerulopathy. Mycophenolate mofetil is an attractive treatment option given its role in the treatment of other complement-mediated diseases and the results of the Spanish Group for the Study of Glomerular Diseases C3 Study. Here, we study the outcomes of patients with C3 glomerulopathy treated with steroids and mycophenolate mofetil.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective chart review of patients in the C3 glomerulopathy registry at Columbia University and identified patients treated with mycophenolate mofetil for at least 3 months and follow-up for at least 1 year. We studied clinical, histologic, and genetic data for the whole group and compared data for those who achieved complete or partial remission (responders) with those who did not achieve remission (nonresponders). We compared remission with mycophenolate mofetil with remission with other immunosuppressive regimens.
RESULTS: We identified 30 patients who met inclusion criteria. Median age was 25 years old (interquartile range, 18-36), median creatinine was 1.07 mg/dl (interquartile range, 0.79-1.69), and median proteinuria was 3200 mg/g creatinine (interquartile range, 1720-6759). The median follow-up time was 32 months (interquartile range, 21-68). Twenty (67%) patients were classified as responders. There were no significant differences in baseline characteristics between responders and nonresponders, although initial proteinuria was lower (median 2468 mg/g creatinine) in responders compared with nonresponders (median 5000 mg/g creatinine) and soluble membrane attack complex levels were higher in responders compared with nonresponders. For those tapered off mycophenolate mofetil, relapse rate was 50%. Genome-wide analysis on complement genes was done, and in 12 patients, we found 18 variants predicted to be damaging. None of these variants were previously reported to be pathogenic. Mycophenolate mofetil with steroids outperformed other immunosuppressive regimens.
CONCLUSIONS: Among patients who tolerated mycophenolate mofetil, combination therapy with steroids induced remission in 67% of this cohort. Heavier proteinuria at the start of therapy and lower soluble membrane attack complex levels were associated with treatment resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical journal of the American Society of Nephrology : CJASN - 13(2018), 3 vom: 07. März, Seite 406-413 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Avasare, Rupali S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.10.2019 Date Revised 13.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2215/CJN.09080817 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM27988785X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM27988785X | ||
| 003 | DE-627 | ||
| 005 | 20231225024056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2215/CJN.09080817 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0932.xml |
| 035 | |a (DE-627)NLM27988785X | ||
| 035 | |a (NLM)29326307 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Avasare, Rupali S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy |b A Case Series |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.10.2019 | ||
| 500 | |a Date Revised 13.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 by the American Society of Nephrology. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: C3 glomerulopathy is a form of complement-mediated GN. Immunosuppressive therapy may be beneficial in the treatment of C3 glomerulopathy. Mycophenolate mofetil is an attractive treatment option given its role in the treatment of other complement-mediated diseases and the results of the Spanish Group for the Study of Glomerular Diseases C3 Study. Here, we study the outcomes of patients with C3 glomerulopathy treated with steroids and mycophenolate mofetil | ||
| 520 | |a DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective chart review of patients in the C3 glomerulopathy registry at Columbia University and identified patients treated with mycophenolate mofetil for at least 3 months and follow-up for at least 1 year. We studied clinical, histologic, and genetic data for the whole group and compared data for those who achieved complete or partial remission (responders) with those who did not achieve remission (nonresponders). We compared remission with mycophenolate mofetil with remission with other immunosuppressive regimens | ||
| 520 | |a RESULTS: We identified 30 patients who met inclusion criteria. Median age was 25 years old (interquartile range, 18-36), median creatinine was 1.07 mg/dl (interquartile range, 0.79-1.69), and median proteinuria was 3200 mg/g creatinine (interquartile range, 1720-6759). The median follow-up time was 32 months (interquartile range, 21-68). Twenty (67%) patients were classified as responders. There were no significant differences in baseline characteristics between responders and nonresponders, although initial proteinuria was lower (median 2468 mg/g creatinine) in responders compared with nonresponders (median 5000 mg/g creatinine) and soluble membrane attack complex levels were higher in responders compared with nonresponders. For those tapered off mycophenolate mofetil, relapse rate was 50%. Genome-wide analysis on complement genes was done, and in 12 patients, we found 18 variants predicted to be damaging. None of these variants were previously reported to be pathogenic. Mycophenolate mofetil with steroids outperformed other immunosuppressive regimens | ||
| 520 | |a CONCLUSIONS: Among patients who tolerated mycophenolate mofetil, combination therapy with steroids induced remission in 67% of this cohort. Heavier proteinuria at the start of therapy and lower soluble membrane attack complex levels were associated with treatment resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Complement Membrane Attack Complex | |
| 650 | 4 | |a Follow-Up Studies | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Immunosuppressive Agents | |
| 650 | 4 | |a Mycophenolic Acid | |
| 650 | 4 | |a Recurrence | |
| 650 | 4 | |a Registries | |
| 650 | 4 | |a Retrospective Studies | |
| 650 | 4 | |a Universities | |
| 650 | 4 | |a complement | |
| 650 | 4 | |a creatinine | |
| 650 | 4 | |a glomerular disease | |
| 650 | 4 | |a glomerulonephritis | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a mycophenolate mofetil | |
| 650 | 4 | |a proteinuria | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Complement C3 |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Creatinine |2 NLM | |
| 650 | 7 | |a AYI8EX34EU |2 NLM | |
| 650 | 7 | |a Mycophenolic Acid |2 NLM | |
| 650 | 7 | |a HU9DX48N0T |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Canetta, Pietro A |e verfasserin |4 aut | |
| 700 | 1 | |a Bomback, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Marasa, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Caliskan, Yasar |e verfasserin |4 aut | |
| 700 | 1 | |a Ozluk, Yasemin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yifu |e verfasserin |4 aut | |
| 700 | 1 | |a Gharavi, Ali G |e verfasserin |4 aut | |
| 700 | 1 | |a Appel, Gerald B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical journal of the American Society of Nephrology : CJASN |d 2006 |g 13(2018), 3 vom: 07. März, Seite 406-413 |w (DE-627)NLM172123720 |x 1555-905X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2018 |g number:3 |g day:07 |g month:03 |g pages:406-413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2215/CJN.09080817 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2018 |e 3 |b 07 |c 03 |h 406-413 | ||